S
SCPH
Scpharmaceutical
This stock has been delisted.
News
Press Releases
Financial Reports
Profile
Reuters·11/05/2025 13:04
MannKind Corporation reports third quarter 2025 revenues of $82.1 million
Dow Jones·10/07/2025 21:09
*News On scPharmaceuticals Inc. (SCPH) Now Under MNKD
TipRanks·10/07/2025 13:44
scPharmaceuticals Completes Merger and Delists from Nasdaq
TipRanks·10/07/2025 13:15
MannKind completes acquisition of scPharmaceuticals
Dow Jones·10/07/2025 13:02
Press Release: MannKind Completes Acquisition of -2-
TipRanks·09/25/2025 08:25
scPharmaceuticals Issues Promissory Note to MannKind
TipRanks·08/29/2025 13:40
Marvell downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
TipRanks·08/29/2025 10:50
scPharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
Reuters·08/29/2025 08:55
U.S. RESEARCH ROUNDUP-Autodesk, Burlington Stores, Ulta Beauty
Dow Jones·08/26/2025 18:11
scPharmaceuticals Price Target Announced at $6.00/Share by Craig-Hallum
Dow Jones·08/26/2025 18:11
scPharmaceuticals Cut to Hold From Buy by Craig-Hallum
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.